Vascular risk factors are associated with faster decline of Alzheimer disease: a longitudinal SPECT study

被引:0
作者
Kazumasa Kume
Haruo Hanyu
Tomohiko Sato
Kentaro Hirao
Soichiro Shimizu
Hidekazu Kanetaka
Hiofumi Sakurai
Toshihiko Iwamoto
机构
[1] Tokyo Medical University,Department of Geriatric Medicine
来源
Journal of Neurology | 2011年 / 258卷
关键词
Alzheimer disease; Hypertension; Diabetes; Hypercholesterolemia; Cerebral blood flow; Progression;
D O I
暂无
中图分类号
学科分类号
摘要
We investigated the effects of cardiovascular risk factors, such as hypertension, diabetes mellitus, and hypercholesterolemia, on longitudinal regional cerebral blood flow (rCBF) changes in Alzheimer’s disease (AD). We followed 68 outpatients with probable AD for an average of 40 months. They were divided into three groups based on no (n = 24), single (n = 27), and multiple (n = 17) vascular risk factors. We assessed longitudinal changes on the Mini-Mental State Examination, Functional Assessment Staging scores, and in rCBF deficits using repeated single photon emission computed tomography (SPECT) using N-isopropyl-p-[123I] iodoamphetamine. During follow-up, the multiple vascular risk factor group showed faster cognitive and functional decline than the no and single vascular risk factor groups. When compared with the initial SPECT, the follow-up SPECT showed a significant rCBF reduction in widespread regions, including the parietotemporal, frontal, and limbic lobes, in the multiple and single vascular risk factor groups, while there was rCBF reduction in small scattered regions of the temporoparietal lobe in the no vascular risk factor group. Multiple vascular risk factors are associated with a greater rate of decline in cognition, function, and rCBF in patients with AD. Our results highlight the contribution of vascular risk factors on the progression of AD.
引用
收藏
页码:1295 / 1303
页数:8
相关论文
共 105 条
[1]  
Beeri MS(2008)Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology Neurology 71 750-757
[2]  
Schmeidler J(2005)Alzheimer’s disease and medical disease conditions: a prospective cohort study J Am Geriatr Soc 53 2235-2236
[3]  
Silverman JM(2004)Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia Am J Geriatr Psychiatry 12 554-570
[4]  
Boksay I(2004)Cholesterol and APOE genotype interact to influence Alzheimer disease progression Neurology 62 1869-1871
[5]  
Reisberg B(1975)Mini-mental state. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 189-198
[6]  
Torossian C(2002)Systolic hypertension in Europe investigators. The prevention of dementia with antihypertensive treatment. New evidence from the systolic hypertension in Europe (Syst-Eur) study Arch Intern Med 162 2046-2052
[7]  
Dougall NJ(1996)Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer’s disease Neurology 47 444-448
[8]  
Bruggink S(2000)Tracking cognitive decline in Alzheimer’s disease using the mini-mental state examination: a meta-analysis Int Psychogeriatr 12 231-247
[9]  
Ebmeier KP(1992)Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type J Clin Exp Neuropsychol 14 575-592
[10]  
Evans RM(2009)Contribution of vascular risk factors to the progression in Alzheimer disease Arch Neurol 66 343-348